Application of TruScreen in detecting ASCUS patients

Weihong Li, Yu Guo, Haiyan Niu, Song Jin, Li Wang

1 Department of Gynaecology and Obstetrics, Affiliated Hospital of Hainan Medical University, Haikou 570102, China
2 Department of Anatomy, Hainan Medical University, Haikou 571101, China; 3 Department of Pathology, Affiliated hospital of Hainan Medical University, Haikou 570102, China

ARTICLE INFO

Article history:
Received 11 June 2011
Received in revised form 11 July 2011
Accepted 5 August 2011
Available online 20 August 2011

Keywords:
TruScreen
ASCUS
Pathology
TCT

ABSTRACT

Objective: To explore the application of cervical cancer screening system, TruScreen in detecting atypical squamous cell of undetermined significance (ASCUS) patients. Methods: A total of 42 cases were selected, who were diagnosed as ASCUS by thinprep cytologic test (TCT). Area from site 15 to 20, site 21 to 32 were detected by TruScreen. And the result was compared with those of cases which had positive pathological result of cervical biopsy. Results: There were 16 cases with abnormal pathological result in ASCUS cases, including 6 cases with CIN I, 6 cases with CIN II, 3 cases with CIN III and 1 case with infiltrating carcinoma. The consistency between TCT and pathological test was 38.10% (16/42). The positive rate of TruScreen at site 15–20 was 61.91% (26/42). There was significant difference in consistency with pathological test between TCT and TruScreen (x²=4.762, P=0.029). The positive rate of TruScreen at site 21–32 was 66.67% (28/42) (Kappa=0.181, P=0.016). There was significant difference in consistency with pathological test between TCT and TruScreen (x²=9.4919, P=0.002). And no case was missed when site 21–32 of patients with CIN II and above were detected by TruScreen. Conclusions: TruScreen is effective in detecting ASCUS patients.

1. Introduction

Cervical cancer is a malignant tumor with the second highest incidence following breast cancer. The morbidity and mortality of cervical cancer in China account for 1/3 of the incidences in the world[1]. It is reported there is 459,000 new cases every year, most of which occurs in China (13,150 cases, 28.7%)[2].

It takes 58 months for development of cervical intraepithelial neoplasia (CIN I) to cancer in situ, and 38 months and 12 months for CIN II and CIN III, respectively[3]. And it takes about 10 years for precancerous lesion to develop into infiltrating carcinom[4]. It is also reported that the incidence is 0.69%–6.20% 4.3%–13.3%, and 12.0%–65.0% for CIN I, CIN II and CIN III to deteriorate into cancer, respectively[5]. The five-year survival rate of cervical cancer patients with surgery at early stage is 80%–90%. So prompt and highly efficient screening is the key to decrease morbidity and to increase cure rate.

The sensitivity and specificity of liquid–based cytological test (TCT) are 73%–94%, and 58%–76%, respectively. It is reported 92.9% cases with squamous intraepithelial lesion (HSIL) and 100.0% squamous cell cancer (SCC) were diagnosed by TCT, compared with 77.8% and 90.9% by traditional smear[6–8].

Cervical cancer is closely related to high risk human papilloma virus (HR-HPV). It is reported HPV DNA was detected in 95%–100% patients[9], and cervical cancer is hardly found in patients with negative HPV[10]. Now hybrid capture (HC) II is regarded as a method with high sensitivity and specificity. It shows highest sensitivity and highest negative predictive value in some research, and has high consistency to the result of hispathological test[11–15].

TruScreen is new real–time photoelectric screening method for cervical cancer. It has been approved in clinical application in Australia, and later gets the certification in Europe and Japan[16]. As cervical lesion occurs, epithelial cell nucleus enlarges, with increasing density and irregular shape, etc. These changes are collected by penetrating
photoelectric wave, then analyzed by database. It is in time, convenient, rapid, and free of wound and pain.

TruScreen has been applied since 2007. It is reported by Singer, Zanardi, Itzkowic, Abdul et al[16–19] and researchers in China[20–23] that combination screening of TruScreen and cervical smear is of high sensitivity, specificity and consistency with pathological result.

2. Materials and methods

2.1. Subjects

A total of 42 cases, who were admitted from December 2010 to May 2011 and were diagnosed as atypical squamous cell of undetermined significance (ASCUS) by TCT, were selected. The age was 22–53 years old.

2.2. Cervical cancer screening system detection

Cervical cancer screening system (Polartechnics Lt.Co., Australian) was used according to manual. Handle controller with disposable inducer was placed into vaginal to probe at site 15–20 and site 21–32.

2.3. Pathological test

The tissues with abnormal result of cervical cancer screening system, TruScreen were selected for biopsy and normal tissues from sites 3, 6, 9 and 12 were also selected for pathological examination.

2.4. Statistic analysis

Kappa consistency test and $\chi^2$ test were carried out for statistic analysis.

3. Results

Pathological results showed 16 cases with positive result, including 6 cases with CIN I, 6 cases with CIN II, 3 cases with CIN III and 1 case with infiltrating carcinoma. The consistency between TCT and pathological test was 38.10% (16/42). The positive rate of TruScreen at site 15–20 was 61.91% (26/42). There were 13 cases with positive result both of pathological test and TruScreen, including 4 cases with CIN I, 5 cases with CIN II, 3 cases with CIN III and 1 case with infiltrating carcinoma. And there were 13 cases with negative result in two tests. Consistency test showed significant consistency between two tests (Kappa = 0.181, $P = 0.016$). There was significant difference in consistency with pathological test between TCT and TruScreen ($\chi^2 = 9.419, P = 0.002$).

4. Discussion

ASCUS is a cell between normal squamous cell and abnormal cell, with higher cellular reactivity but not as high as cervical squamous intraepithelial neoplasia in quality and quantity[1]. Due to incomplete tissue morphology of smear, it is difficult to determine the existence of squamous intraepithelial neoplasia. ASCUS is a common type with low repetitiveness of test. Detection rate of invasive carcinoma of cervix and precancerous lesion are low in ASCUS patients[25].

Pathological positivity of ASCUS patients is 38.1% in this study, and incidence of patients with CIN II and above is 62.5% (10/16). It indicates ASCUS need be paid more attention to. It is proposed that vaginoscopy is necessary for ASCUS patients[26]. Some proposed that repetitive cytological test should be performed[27], and some held the point that HPV should be tested firstly, and then vaginoscopy is used if the result is positive[28]. It is reported by Song et al positive rate of HR HPV DNA is 40%–51%, HR HPV DNA test can be performed by HC–2 method separate ill–free people and sick patients[25].

Zanardi et al conducted a study on 37 cases diagnosed as ASCUS by cytological test. The consistency between TruScreen and pathological test was 81%. They thought TruScreen can make effective screening on ASCUS patients or patients with unclear cytological result. We use Kappa consistency test to determine the consistency between TruScreen and pathological result, and it showed significant consistency (Kappa = 0.279, $P = 0.043$ for site 15–20, and Kappa = 0.181, $P = 0.016$ for site 21–32). It indicates that result of TruScreen is consistent to pathological result, and TruScreen is helpful in screening ASCUS patients. Besides, no case with high CIN level was missed. It indicates that in contrast to HR HPV DNA test, TruScreen is more helpful in separation of ASCUS patients. Due to limited cases, the value of TruScreen need further investigation with larger cases.

Conflict of interest statement

We declare that we have no conflict of interest.
References

[1] Lang JH. Change and opportunity of prevention of cervical cancer in the world. *Chinese J Obstet & Gynecol* 2002; 3: 8–10.

[2] Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55(2): 74–108.

[3] Zhao XD, Zhang Y. Treatment of cervical intraepithelial neoplasia. *Foreign Medical Sci (Obstet Gynecol Fascicle)* 2007; 1: 47–50.

[4] Renshaw AA, Young NA, Birdsong GG, Styer PE, Davey DD, Mody DR, et al. Comparison of performance of conventional and ThinPrep gynecologic preparations in the College of American Pathologists Gynecologic Cytology Program. *Arch Pathol Lab Med* 2004; 128(1): 17–22.

[5] Yang L, Zhang SW, Sun XD, Mu R, Qiao YL. Changes of mortality rate for cervical cancer during 1970’s and 1990’s periods in China. *Acta Academiae Med Sinicae* 2003; 4: 386–890.

[6] Hutchinson ML, Zahniser DJ, Sherman MS, Herrero R, Alfaro M, Bratti MC, et al. Utility of liquid–based cytology for cervical carcinoma screening. *Cancer Cytopathol* 2008; 87(2): 48–55.

[7] Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. American Society for Colposcopy and Cervical Pathology–sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. *Am J Obstet Gynecol* 2007; 197(4): 346–355.

[8] Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. American Society for Colposcopy and Cervical Pathology–sponsored Consensus Conference: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. *Am J Obstet Gynecol* 2007; 197(4): 340–345.

[9] Thomas DB, Qin Q, Kuyper J, Kivist N, Ashley IL, Koetsawang A, et al. Human papillomaviruses and cervical cancer in Bangkok. II. Risk factors for in situ and invasive squamous cell cervical carcinomas. *Am J Epidemiol* 2001; 153(8): 732–739.

[10] Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low–resource settings. *J Natl Cancer Inst* 2000; 92(10): 818–825.

[11] Cuijck J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus–based and other novel options for cervical cancer screening in developing and developing countries. Vaccine 2008; 26(Suppl 10): K29–K41.

[12] Naucler P, Wyd T, Tomberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. *J Natl Cancer Inst* 2009; 101(2): 88–99.

[13] Kjaer S, Hoasdall E, Frederiksenk, Munk C, van den Brule A, Svere E, et al. The absolute risk of cervical abnormalities in high–risk human papillomavirus–positive, cytologically normal women over a 10–year period. *Cancer Res* 2006; 66: 10630–10636.

[14] Kate S, Heather A. The role of human papillomavirus testing in cervical cancer screening. *J Clinical Virol* 2005; 32–34.

[15] Brink AA, Snijders PJ, Meijer CJ, Berkhoj J, Verheijen RH. HPV testing in cervical screening. *Best Pract Res Clin Obstet Gynaecol* 2006; 20(2): 253–266.

[16] Pisol N. Real time screening techniques in the detection of cervical cancer. *Otol&Gynae Product News* 2008; 3: 30–34.

[17] Singer A, Coppleson M, Canfell K, Skladnev V, Mackellar G, Pisol N, et al. A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: A multicenter evaluation. *Int J Gynecol Cancer* 2003; 13: 804–811.

[18] Zanardi C, Camerini T, Buocolo C, Bologna, Faenza. TruScreen: a new ally in cervical cancer screening. *Ginecommera* 2004 ; 3: 325–330.

[19] Itzkow A. TruScreen: the Australian experience. In: *Cervical cancer: Not yet beaten and at what cost?* Sydney, NSW: Proceedings of the Third Annual Clinical Symposium on Cervical cancer.; 2005.

[20] Abdul S, Brown B, Milnes P, Tidy J. The use of electrical impedance spectroscopy in the detection of cervical intraepithelial neoplasia. *Int J Gynecol Cancer* 2006; 16(5): 1823–1832.

[21] Lv SJ, Huang LY, Zhao X, Xue X, Tong XW, Wu QY. Comparing study of cervical cancer screening system and liquid–based cytology test in the screening of cervical lesions. *Progr Obstet & Gynecol* 2009; 18(2): 90–93.

[22] Zhang LP, Zhang SP, Li WJ, Feng LM. Application of TruScreen in detection of patients with positive result of TCT test. *China Healthcare Innovation* 2009; 4(23): 62–63.

[23] Li WH, Jin S, Zhang JX, Wu XM, Zeng RR, Wang L. Efficacy comparison of cervical cancer screening system and liquid based cytology test in detection of cervical lesions. *J Hainan Med College*, 2010; 16(9): 1129–1134.

[24] Zhu MP. The pathologic diagnosis of 106 cases with atypical squamous cells of undetermined significance(ASCUS) in cervix. *J Oncol* 2008; 14(6): 487–489.

[25] Song XH, Xu XH, Bi H, Wei LH. Treatment and diagnosis of patients with abnormal cervical screening result. *Curr Advance Obst & Gynecol* 2009; 18(2): 83–89.

[26] Emerson RE, Puzanov A, Burmener C. Long term follow up of women with atypical squamous cells of undetermined significance (ASCUS). *Diagn Cytopathol* 2002; 27(3):153–157.

[27] Morin C, Bairati I, Bouchard C, Fortier M, Roy M, Moore L, et al. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. *J Reprod Med* 2001; 46(9): 799–805.

[28] Li YL, Yang YZ. Significance of detection of HPV subtype in management of cervical lesion shunt. *Chinese J Practical Gynecol & Obst* 2007; 23(7): 501–503.